Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy

[Emily]

https://www.sciencedirect.com/science/article/pii/S1530891X2101079X
Kristina M. Cross, Dylan M. Landis, Laveena Sehgal, J. Drew Payne,
Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy,
Endocrine Practice,
Volume 27, Issue 8,
2021,
Pages 850-855,
ISSN 1530-891X,
https://doi.org/10.1016/j.eprac.2021.06.001.
(https://www.sciencedirect.com/science/article/pii/S1530891X2101079X)
Abstract: Objective
To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19.
Methods
Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included.
Results
The results showed that melatonin acts to reduce reactive oxygen species–mediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19.
Conclusion
These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis.

Keywords: melatonin; COVID-19; viral diseases; SARS-CoV-2; antioxidant; anti-inflammatory agent